11:44 AM EDT, 08/01/2024 (MT Newswires) -- Denali Therapeutics ( DNLI ) shares fell nearly 4% in recent Thursday trading after the company swung to a Q2 net loss.

The company reported a Q2 loss Thursday of $0.59 per diluted share, compared with earnings of $1.30 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.70.

The company reported no collaboration revenue for the quarter that ended June 30, compared with $294.1 million a year earlier.

Analysts surveyed by Capital IQ expected revenue of $13.3 million.

The company said its cash, cash equivalents, and marketable securities were about $1.35 billion as of June 30.

Price: 23.44, Change: -0.93, Percent Change: -3.82